Skip to main content
Log in

Complete biochemical control and pituitary adenoma disappearance in a child with gigantism: Efficacy of octreotide therapy

  • Letter to the Editor
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Abe T, Tara LA, Lüdecke DK. Growth hormone-secreting pituitary adenomas in childhood and adolescence: features and results of transnasal surgery. Neurosurgery 1999, 45: 1–10.

    Article  CAS  PubMed  Google Scholar 

  2. Bergamaschi S, Ronchi CL, Giavoli C, et al. Eight-yearfollow-up of a child with a GH/prolactin-secreting adenoma: efficacy of pegvisomant therapy. Horm Res Paediatr 2010, 73: 74–9.

    Article  CAS  PubMed  Google Scholar 

  3. Schoof E, Dörr HG, Kiess W, et al. Five-year follow-up of a 13-year-old boy with a pituitary adenoma causing gigantism—effect of octreotide therapy. Horm Res 2004, 61: 184–9.

    Article  CAS  PubMed  Google Scholar 

  4. Goldenberg N, Racine MS, Thomas P, Degnan B, Chandler W, Barkan A. Treatment of pituitary gigantism with the growth hormone receptor antagonist pegvisomant. J Clin Endocrinol Metab 2008, 93: 2953–6.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  5. Maheshwari HG, Prezant TR, Herman-Bonert V, Shahinian H, Kovacs K, Melmed S. Long-acting peptidomimergic control of gigantism caused by pituitary acidophilic stem cell adenoma. J Clin Endocrinol Metab 2000, 85: 3409–16.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ciresi, A., Amato, M.C., Galluzzo, A. et al. Complete biochemical control and pituitary adenoma disappearance in a child with gigantism: Efficacy of octreotide therapy. J Endocrinol Invest 34, 162–163 (2011). https://doi.org/10.1007/BF03347049

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03347049

Keywords

Navigation